Obagi Medical Products, Inc. (OMPI) Tops Q2 EPS by 2c, Posts Q3 Guidance
Tweet
Share
E-mailGet Alerts OMPI Hot Sheet
Join SI Premium – FREE
Obagi Medical Products, Inc. (NASDAQ: OMPI) reported Q2 EPS of $0.18, $0.02 better than the analyst estimate of $0.16. Revenue for the quarter came in at $28.88 million versus the consensus estimate of $27.49 million.
Obagi Medical Products, Inc. sees Q3 2011 EPS of $0.16-$0.17, versus the consensus of $0.18. Non-GAAP EPS is expected to be in the range of $0.75-$0.78. Obagi Medical Products, Inc. sees Q3 2011 revenue of $27-$28.5 million, versus the consensus of $28 million.
Obagi Medical Products, Inc. sees Q3 2011 EPS of $0.16-$0.17, versus the consensus of $0.18. Non-GAAP EPS is expected to be in the range of $0.75-$0.78. Obagi Medical Products, Inc. sees Q3 2011 revenue of $27-$28.5 million, versus the consensus of $28 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Cineverse Corp (CNVS) Misses Q1 EPS by 20c; Offers Guidance
- LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
